Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.
about
Pomegranate Juice Metabolites, Ellagic Acid and Urolithin A, Synergistically Inhibit Androgen-Independent Prostate Cancer Cell Growth via Distinct Effects on Cell Cycle Control and ApoptosisTwenty Years of PSA: From Prostate Antigen to Tumor MarkerRelationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillanceMolecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targetsRisk assessment for prostate cancer metastasis and mortality at the time of diagnosisImmunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate CancerPSA and beyond: alternative prostate cancer biomarkersValidation of proposed prostate cancer biomarkers with gene expression data: a long road to travelProstate-specific Antigen Velocity Risk Count to Discern Significant From Indolent Prostate CancerCo-occurring gland angularity in localized subgraphs: predicting biochemical recurrence in intermediate-risk prostate cancer patientsPSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of AgingDoes prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging.Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data.Prostate cancer--to screen, or not to screen, is that the question?Hypermethylation of genes for diagnosis and risk stratification of prostate cancerTransperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial.Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer.Predicting 15-year prostate cancer specific mortality after radical prostatectomy.Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by FluorescenceDistribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of Aging.Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.Active surveillance for prostate cancer: patient selection and management.Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes.Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservativelyActive surveillance in men with low-risk prostate cancer: current and future challenges.Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.Significance of preoperative PSA velocity in men with low serum PSA and normal DRE.An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detectionComorbidity and mortality results from a randomized prostate cancer screening trial.Prognostic factors in prostate cancer.An inexpensive, fast and sensitive quantitative lateral flow magneto-immunoassay for total prostate specific antigenProstate cancer screening and determining the appropriate prostate-specific antigen cutoff values.Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection?Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancerChanges in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trialsProstate kallikrein markers in diagnosis, risk stratification and prognosis.Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomyBest practice in primary care pathology: review 4Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.
P2860
Q21285102-A116F375-87BD-4A14-9312-77056AE894BEQ24564782-4694A322-3C71-40E4-9FF3-F1C56CB76CC9Q24627957-D731D815-F0A9-4872-AC6B-25DCD500A3A4Q24629083-65301438-A613-403C-8CE9-9D657783D317Q24645292-5917E9FE-57B6-493B-8876-FA42E3590DA1Q26767044-6303E7E8-AFF3-4139-A3AF-2D514876E47CQ26770646-BFCDA187-DCCB-40D6-81E8-8B862D85ABE7Q27001399-4F8CA33B-00DE-4EC9-8C75-CD1520A9FE84Q27023073-8FBA9DF2-308A-4559-A163-E07B882BB254Q28539180-D3BAE275-50CA-4619-B1F2-B7DF35E94730Q31162100-0DC4DFB0-93D4-4D11-93DA-D183845F25ECQ31171895-CCD283CF-9E33-489A-9B1F-800BB69ED81EQ33374219-0C30D56F-A060-4F0E-9536-7F6009D4F818Q33395534-8E737666-1344-445E-8D4A-E18BAA339991Q33410858-6B0BE3AD-DAEF-4BC2-959F-20EBABD84DAAQ33724715-4AF224E7-80EA-4A87-BB70-772CA9F6061BQ33745069-25821D39-4A16-4B18-B1C1-33A5B19EEC95Q33759725-53B85994-98FA-47F1-B3D4-66B51B084C84Q33759991-AB13C5B4-9509-4E84-98E3-BD04AC4ECB67Q33783135-E36325F4-6598-4E53-A784-DA26DDF083DAQ34086557-DF890BC7-BA18-49F9-ADC8-93C1889506E9Q34111584-F2FC3847-6872-4381-BF63-B01B1983DD10Q34288148-46703453-8962-412A-B910-373FC4A2D0B2Q34332454-9FC7A6E6-DBA3-44BD-9781-69B2193530D6Q34448113-E11D38E4-484C-4379-AECE-F59FB90EF36AQ34482255-DCF5DB40-EAE5-4A99-B98E-F52FC08B0313Q34554130-DA8C1043-DD67-47F4-B282-7B153BF2E3EBQ34677200-4846ADCE-7CF2-413A-BEB3-81766ADF5454Q34679266-5A1F937B-B88A-4700-B5DE-0C8DA34921DEQ34682069-0EE640DB-1987-454F-BD1B-9CDA15E9B824Q34686686-92DA85E8-ACBE-44A4-8219-594A9985594EQ35022732-0D47B7EC-48C4-41EA-80F4-B5374B664FE9Q35070443-FA7DFCF6-890E-40A3-B31C-53E40BA4B044Q35118406-D3EEDB18-F6B1-4D7F-8FA7-140866961651Q35158676-444364B2-E321-443D-9BAB-3ECBF9CAD531Q35656240-B58738E2-2E97-4699-A9D1-A5C08A752861Q35683035-7625624F-6D05-486D-93B6-9E41E5CC2D97Q35748251-B21BE663-9DF1-4C3C-9A20-3D7A09482671Q35770305-71CD69F9-28ED-45DE-AA93-91DBFC45F4A2Q35917103-05AA962F-151F-42EF-A8AC-55AFD7C3FE34
P2860
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Preoperative PSA velocity and ...... r after radical prostatectomy.
@ast
Preoperative PSA velocity and ...... r after radical prostatectomy.
@en
Preoperative PSA velocity and ...... r after radical prostatectomy.
@nl
type
label
Preoperative PSA velocity and ...... r after radical prostatectomy.
@ast
Preoperative PSA velocity and ...... r after radical prostatectomy.
@en
Preoperative PSA velocity and ...... r after radical prostatectomy.
@nl
prefLabel
Preoperative PSA velocity and ...... r after radical prostatectomy.
@ast
Preoperative PSA velocity and ...... r after radical prostatectomy.
@en
Preoperative PSA velocity and ...... r after radical prostatectomy.
@nl
P2093
P356
P1476
Preoperative PSA velocity and ...... r after radical prostatectomy.
@en
P2093
Anthony V D'Amico
Kimberly A Roehl
Ming-Hui Chen
William J Catalona
P304
P356
10.1056/NEJMOA032975
P407
P577
2004-07-01T00:00:00Z